Puma Biotechnology (PBYI) Research & Development (2012 - 2026)
Puma Biotechnology's (PBYI) quarterly Research & Development came in at $19.8 million in Q1 2026, up 42.79% YoY from $13.9 million in Q1 2025, and up 17.54% on a QoQ basis from $16.8 million in Q4 2025.
Puma Biotechnology (PBYI) Research & Development (2012 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 15 years of Research & Development data on file, last reported at $19.8 million in Q1 2026.
- Quarterly Research & Development rose 42.79% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.0 million (up 23.16% YoY) and the FY2025 annual result came in at $62.1 million, up 12.98% from the prior year.
- Research & Development rose to $19.8 million in Q1 2026, from $16.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $19.8 million in Q1 2026 to a low of $7.0 million in Q3 2022.
- A 5-year average of $13.8 million and a median of $13.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development plunged 62.84% — and 2023, when it soared 63.51%.
- Tracing PBYI's Research & Development over 5 years: stood at $13.8 million in 2022, then retreated by 6.61% to $12.9 million in 2023, then grew by 17.84% to $15.2 million in 2024, then advanced by 11.02% to $16.8 million in 2025, then advanced by 17.54% to $19.8 million in 2026.
- The last three Research & Development figures came in at $19.8 million (Q1 2026), $16.8 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 18.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.90 Mn |
| Mar 31, 2026 | 19.80 Mn |
| Dec 31, 2025 | 16.84 Mn |
| Sep 30, 2025 | 15.91 Mn |
| Jun 30, 2025 | 15.45 Mn |
| Mar 31, 2025 | 13.86 Mn |
| Dec 31, 2024 | 15.17 Mn |
| Sep 30, 2024 | 12.55 Mn |
| Jun 30, 2024 | 13.63 Mn |
| Mar 31, 2024 | 13.59 Mn |
| Dec 31, 2023 | 12.87 Mn |
| Sep 30, 2023 | 11.45 Mn |
| Jun 30, 2023 | 13.36 Mn |
| Mar 31, 2023 | 12.71 Mn |
| Dec 31, 2022 | 13.78 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Jun 30, 2022 | 11.97 Mn |
| Mar 31, 2022 | 15.24 Mn |
| Dec 31, 2021 | 14.17 Mn |
| Sep 30, 2021 | 18.84 Mn |